Dr Heather Wakelee from Stanford University speaks to ecancer about the treatment of non-small cell lung cancer (NSCLC) patients during the COVID-19 pandemic.
Initially she outlines the important safety measures undertaken by her department to reduce the spread of coronavirus around cancer patients.
Dr Wakelee then discusses why NSCLC patients may be at higher risk, as well as how she has been prioritising patients, and treatment. Her overriding conclusion is a significant increase in telemedicine and remote treatment where possible.
Furthermore, Dr Wakelee explains the differences when treating ALK patients, and whether there are complications which may be exacerbated by coronavirus symptoms.
This programme has been supported by an unrestricted educational grant from Takeda.